PlainPharmaWatch

CMS Open Payments · Program Year 2024

EyePoint Pharmaceuticals US, Inc.

EyePoint Pharmaceuticals US, Inc. reported $9,673,376.83 in payments to 748 physicians and teaching hospitals across 902 transactions.

See the rankings → How this is sourced
$9.7M
Total payments
902
Transactions
748
Recipients
+$331.3K
General Payments vs PY2023

EyePoint Pharmaceuticals US, Inc. reported $9,673,376.83 in payments to 748 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #181 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $12.9K per recipient across 5 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

EyePoint Pharmaceuticals US, Inc. pairs top-10% payment volume with a broadly spread payment pattern across many recipients.

#181
of 1,925 companies
0.1%
of all US industry payments
0.1%
paid to its single top recipient
5
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

EyePoint Pharmaceuticals US, Inc.'s CMS-reported General Payments increased by $331.3K (+66.7%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: EYEPOINT US, INC.PY2023: EYEPOINT US, INC.PY2024: EyePoint Pharmaceuticals US, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$496.5KPY2024$827.8K
PY2023
$496,515.66
PY2024
$827,774.45

How EyePoint Pharmaceuticals US, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

EyePoint Pharmaceuticals US, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$9,673,377 Top 9% higher than 91% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for EyePoint Pharmaceuticals US, Inc.

Averaging $10.7K per transaction and $12.9K per recipient, EyePoint Pharmaceuticals US, Inc.'s Program Year 2024 total comes to $9,673,376.83 across 902 transactions and 748 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #181 of 1,925 companies, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.

Of the 5 general-payment categories charted below, "Consulting Fee" is the largest at $695.2K across 192 transactions, 7.2% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 5 types of general payments, EyePoint Pharmaceuticals US, Inc.'s largest category was "Consulting Fee" at $695.2K - 7.2% of the company's reported total.

How EyePoint Pharmaceuticals US, Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$695.2K2. Travel and Lodging$86.7K3. Food and Beverage$44.4K4. Gift$1.4K5. Education$39.98
Payment Type Amount Transactions
Consulting Fee $695.2K 192
Travel and Lodging $86.7K 179
Food and Beverage $44.4K 368
Gift $1.4K 8
Education $39.98 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $413,264.22 (49.9%) of $827,774.45 in this company's General Payments records across 220 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for EyePoint Pharmaceuticals US, Inc.

The five named recipients with the highest reported General Payments from this company

Carl D Regillo$117.2KCHARLES Clifton WYKOFF$115.9KDavid S Boyer$102.8KDavid Guyer$59.4KDAVID Aarron EICHENBAUM$17.9K
  1. 1

    Carl D Regillo

    $117,237.23 across 13 reported transactions

  2. 2

    CHARLES Clifton WYKOFF

    $115,943.55 across 9 reported transactions

  3. 3

    David S Boyer

    $102,767.46 across 4 reported transactions

  4. 4

    David Guyer

    $59,438.59 across 2 reported transactions

  5. 5

    DAVID Aarron EICHENBAUM

    $17,877.39 across 18 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $10.7K. Average per recipient: $12.9K.

Total Amount

$9,673,376.83

Avg per Transaction

$10.7K

Avg per Recipient

$12.9K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

EyePoint Pharmaceuticals US, Inc. Share

0.1%

#181 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to EyePoint Pharmaceuticals US, Inc.

Route 92 Medical, Inc.

$9.7M 774 recipients

Dermavant Sciences, Inc.

$9.7M 73,486 recipients

Supernus Pharmaceuticals, Inc.

$9.7M 61,253 recipients

H. Lundbeck A S

$9.8M 303 recipients

W. L. Gore & Associates, Inc.

$9.5M 25,860 recipients

Applied Medical Research, Inc

$10.0M 0 recipients

Frequently Asked Questions

How much did EyePoint Pharmaceuticals US, Inc. pay to physicians and hospitals in 2024? ▾
EyePoint Pharmaceuticals US, Inc. made $9,673,376.83 in payments to physicians and hospitals in Program Year 2024, across 902 individual transactions. This represents 0.1% of all industry payments reported to CMS Open Payments.
How many physicians received payments from EyePoint Pharmaceuticals US, Inc.? ▾
748 physicians and teaching hospitals received payments from EyePoint Pharmaceuticals US, Inc. in 2024, averaging $12.9K per recipient.
What types of payments did EyePoint Pharmaceuticals US, Inc. make? ▾
EyePoint Pharmaceuticals US, Inc. made 5 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Consulting Fee" at $695.2K, representing 7.2% of the company's reported total.
How does EyePoint Pharmaceuticals US, Inc. rank among pharmaceutical companies? ▾
EyePoint Pharmaceuticals US, Inc. ranks #181 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from EyePoint Pharmaceuticals US, Inc.? ▾
The average transaction from EyePoint Pharmaceuticals US, Inc. was $10.7K in 2024. The company made 902 total transactions to 748 recipients.
Where does the payment data for EyePoint Pharmaceuticals US, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download EyePoint Pharmaceuticals US, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.